Peregrine Capital Management’s Myriad Genetics MYGN Stock Holding History

Peregrine Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-342,845	Closed	-$4.7M	–	335
2024 Q4	$4.7M	Buy	342,845 +36,958	+12%	+$682K	0.14%	229
2024 Q3	$8.38M	Buy	305,887 +670	+0.2%	+$18.1K	0.25%	103
2024 Q2	$7.47M	Buy	305,217 +3,960	+1%	+$86.9K	0.22%	153
2024 Q1	$6.42M	Buy	301,257 +75	+0%	+$1.61K	0.18%	191
2023 Q4	$5.76M	Buy	301,182 +20,415	+7%	+$353K	0.17%	211
2023 Q3	$4.5M	Sell	280,767 -17,622	-6%	-$335K	0.13%	236
2023 Q2	$6.92M	Buy	+298,389	New	+$6.51M	0.19%	221

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Peregrine Capital Management's MYGN Position: Q1 2025 in Review

Peregrine Capital Management sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 342,845 shares — an estimated $4.7M sold.

Peregrine Capital Management first reported a position in MYGN in Q2 2023 and held it in 7 quarters. The position peaked at $8.38M in Q3 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Peregrine Capital Management reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Peregrine Capital Management sold 342,845 Myriad Genetics shares in Q1 2025, an estimated $4.7M.
Peregrine Capital Management first reported a position in Myriad Genetics in Q2 2023 and held it in 7 quarters.
Peregrine Capital Management's Myriad Genetics position peaked at $8.38M in Q3 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Peregrine Capital Management's 13F filing for Q1 2025, filed 25 Apr 2025.